A new epilepsy treatment from Belgian drugmaker UCB helped reduce the rate of seizures in a Phase III trial, the company said, setting the stage for an FDA application and a shot at widening its footprint in the field.
The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
President Obama's Brain Initiative awarded millions to University of California researchers to develop mini brain implants that treat Parkinson's disease and epilepsy.
The FDA has rejected Acorda Therapeutics' nasal spray for epilepsy, throwing a wrench in the biotech's plan for a quick trip to the market with its orphan drug.
Quest Diagnostics is rolling out a new line of epilepsy tests against the backdrop of a continued struggle to generate solid revenue growth. In the wake of depressing 2014 first-quarter numbers, those new products could be a step toward helping the New Jersey company turn the tide.
A new patch-like device designed by engineers at the University of Texas at Austin boasts a number of functions, including drug delivery for patients with movement disorders such as epilepsy or Parkinson's disease.
As interest in NeuroPace's new RNS neuromodulation antiepilepsy implant ramps up, The New York Times tracked down some of the patients who use the device and have experienced major improvements in their quality of life.
California's NeuroPace gained the FDA's long-awaited signoff for its antiepilepsy neurostimulation implant, capping years of development and testing.
The FDA has approved Sunovion's Aptiom (eslicarbazepine), an add-on therapy designed to prevent epilepsy seizures. "Some patients with epilepsy do not achieve satisfactory seizure control from existing treatments," said Dr. Eric Bastings, acting director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.
The software is the result of a three-year effort by Rhenovia and its collaborators to develop a computer model for epilepsy that is validated by laboratory experiments. Having created the software, Rhenovia is looking to market it to biopharma companies. The platform could help identify new therapeutic candidates--or reposition existing molecules--and assess their toxicology and safety profiles.